# Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

> **NCT06637332** · PHASE4 · RECRUITING · sponsor: **Todd C. Lee MD MPH FIDSA** · enrollment: 300 (estimated)

## Conditions studied

- Staphylococcus Aureus Septicemia
- Staphylococcus Aureus Bacteremia
- S. Aureus Bacteremia
- S. Aureus Bloodstream Infection
- Staphylococcus Aureus Endocarditis

## Interventions

- **DRUG:** Daptomycin for Injection
- **DRUG:** Vancomycin (IV)

## Key facts

- **NCT ID:** NCT06637332
- **Lead sponsor:** Todd C. Lee MD MPH FIDSA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-14
- **Primary completion:** 2027-01
- **Final completion:** 2027-11
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06637332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06637332, "Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06637332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*